Search PubMed⌕ Search

Biomedical subjects

U Olsson

Publications and source records attributed to U Olsson.

65 records · Page 4Linked to original sources

Effects of dimethylnitrosamine on metabolism of N,N-dimethylaniline by rat liver microsomes. A comparative study of treatment in vivo, in isolated liver perfusion and in the microsomal system.

The effect of dimethylnitrosamine (DMN) on rat liver microsomal detoxication was studied, using the non-carcinogenic aromatic amine N,N-dimethylaniline (dimethylaniline) as substrate. Prior to the preparation of microsomes, the rat liver was exposed to DMN either in vivo (by i.p. injection) or in the isolated liver perfusion system (by addition to the perfusion medium). DMN treatment in vivo (20 mg/kg body wt.) caused a 40% increase in dimethylaniline N-oxygenation and a 30% decrease in dimethylaniline C-oxygenation. When DMN was added to the perfusion medium to a final concentration of 5 or 25 mM, a similar effect was observed. With the 5 mM dose, C-oxygenation was decreased by 20% with a non-significant increase in N-oxygenation. The higher dose caused a 50% increase in N-oxygenation, whereas the decrease in C-oxygenation remained at 20%. When microsomes were incubated with both DMN (5 mM) and dimethylaniline (5 mM) in the system, a small but significant decrease in both N- and C-oxygenation of dimethylaniline was observed. The effect of DMN on the amino acid incorporation into liver and plasma proteins was also studied in the liver perfusion system. The synthesis of both liver and plasma proteins was reduced by DMN.

Aniline Compounds↗

Inheritance of type-III hyperlipoproteinemia. Lipoprotein patterns in first-degree relatives.

The lipoprotein (LP) patterns were studied in the families of 19 index cases with type-III hyperlipoproteinemia (HLP). Seventy adult first-degree relatives (93% ascertainment) to the 19 probands were analyzed. The diagnosis of HLP type III among the first-degree relatives was based on three criteria, all of which had to be fulfilled to make the diagnosis: (1) presence of a slow-moving band in very-low-density LP (VLDL) on agarose gel electrophoresis migrating in beta or close to beta position; (2) A cholesterol/triglyceride ratio (mg/100 ml: mmoles/liter) in VLDL greater than 29.0; and (3) A "III-index" [cholesterol/triglycerides in VLDL x 10 divided by cholesterol/triglycerides in low-density LP (LDL)] greater than 1.30. When defined according to these criteria there was a marked over-representation of HLP type III among the relatives (27%). There was also an increased frequency of hypertriglyceridemia (28% against expected 15%), mainly because of a high prevalence of HLP type IV (24%). On agarose gel electrophoresis a "late pre-beta" band, probably indicative of an increased amount of intermediary LP particles, was frequently present (47%) among relatives not classified as HLP type III. Type-III patients with hypertriglyceridemia were characterized by a significantly higher body weight than those with normotriglyceridemic type III. However, there was no qualitative difference in the composition of the lipoproteins in normotriglyceridemic and hypertriglyceridemic type-III patients. A genetic analysis of the LP patterns within the families showed several examples of vertical transmission of HLP type III. There was no sex linkage. Six of thirteen analyzed parents showed LP patterns classified as HLP type III. Another two parents were most probably carriers of the gene. Of the siblings to the probands, 23% showed a type-III pattern and another four (7%) showed LP patterns very similar to type III, fulfilling two of three criteria for HLP type III. The data support the concept that HLP type III is inherited as an autosomal dominant gene. It was indicated that HLP type IV with a late pre-beta band in VLDL may represent another expression of the gene for HLP type III. It is suggested that HLP type III may be a pathogenetically heterogenous group of lipid disorders. A separation of type III into two subgroups with low or normal and high LDL cholesterol concentration, respectively, may facilitate the understanding of the inheritance of type III as well as of the pathogenesis behind this LP abnormality.

Adult↗

Lipoprotein composition and lipoprotein interrelations in 50-year-old men with hyperlipoproteinaemia.

The serum lipoprotein (LP) composition and LP lipid interrelations were studied in 50-year-old men with different types of hyperlipoproteinaemia (HLP) and in randomly sampled health controls from the same population. The ratio cholesterol/triglycerides in very low density lipoproteins (VLDL)was high in HLP type III. The other types of HLP showed ratios not significantly different from the controls. The low density lipoprotein (LDL) cholesterol concentration was similar in controls, type III and type IV while, by definition, higher values were seen in type II A and II B. All types of HLP showed statistically significantly higher LDL triglycerides than the controls. HLP type II A and II B showed cholesterol/triglyceride ratios in LDL similar to the controls. The corresponding ratio in type IV was lower than in the control subjects but the lowest ratio was seen in type III with a mean value below the 5th percentile of healthy controls. The high density lipoprotein (HDL) cholesterol concentration was decreased in HLP type IV. Apparently elevated HDL triglyceride levels were seen in all types of HLP with the highest mean value in type III. The LP lipid interclass relationships were analysed in the random sample of health men and compared to corresponding relationships in the different types of HLP. Apart from HLP type III and HLP type IV with low LDL cholesterol levels all other types of LP interconversions. Intype IV a significant negative correlation between VLDL concentration and LDL cholesterol concentration and the cholesterol/triglyceride ratio in VLDL. There were no significant correlations between LDL cholesterol concentration and VLDL lipid variables in other types of HLP and normolipidaemia.

Age Factors↗

Intra-articular injection of non-animal stabilised hyaluronic acid (NASHA) for osteoarthritis of the hip: a pilot study.

OBJECTIVES: This study was undertaken to assess the safety and potential efficacy of intra-articular non-animal stabilised hyaluronic acid (NASHA) in patients with hip OA. METHODS: This was a prospective, open-label, 3-month pilot study of a single intra-articular injection of NASHA in 31 patients. Safety outcomes were measured at 2 weeks and 3 months after treatment, as were efficacy measurements including WOMAC pain, stiffness and physical function scores, and the patient assessment of global disease status. Patients demonstrating reduced pain at month 3 participated in an extension phase (assessment at 6-11 months, 18 patients). Positive response was defined as a > or = 40% reduction in the WOMAC pain score from baseline, together with an absolute decrease of > or = 5 points. RESULTS: Intra-articular injection of NASHA into the hip was well tolerated. The only treatment-related AE was exacerbation of pain and/or stiffness in the treated hip (reported by 9 patients) and there were no serious AEs. The response rate to treatment was 50% at 2 weeks and 54% at 3 months. In the extension population, response rates of 69% and 44% were observed at month 3 and the extension visit, respectively. Global disease status was improved at month 3 compared with baseline in 68% of the patients. CONCLUSIONS: Our results show that a single intra-articular injection of NASHA is a well tolerated and potentially effective therapy in the treatment of hip OA. Further studies of NASHA in this setting are warranted.

Adjuvants, Immunologic↗